Search Result

Results for "

glucose-induced

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SGLT (1) Apoptosis (1) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) CGRP Receptor (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) GCGR (4) HDAC (1) Keap1-Nrf2 (1) Neuropeptide Y Receptor (1) Phospholipase (1) PKC (2) Reactive Oxygen Species (3)
By Research Areas:	Cancer (1) Cardiovascular Disease (4) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (12) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108611

AACOCF3 2 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P1401

Protein Kinase C (19-36)	PKC	Metabolic Disease
Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC₅₀ of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-126415

Magnesium Lithospermate B	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroinﬂammation and attenuates neurodegeneration .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Reactive Oxygen Species	Metabolic Disease
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-129297

CMPF	Endogenous Metabolite	Metabolic Disease
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-13413

Tofogliflozin (hydrate) 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific *sodium/glucose* cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2** . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .

HY-108600

CGP-53353 DAPH-7	PKC DNA/RNA Synthesis	Cardiovascular Disease Metabolic Disease
CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC₅₀s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients .

HY-13755

Sulforaphane Maximum Cited Publications 33 Publications Verification	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species	Inflammation/Immunology Cancer
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-P0055

GLP-1(7-37)

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

GLP-1(7-37) 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0055A

GLP-1(7-37) acetate 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P5796

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

Cat. No.	Product Name	Target	Research Area

HY-P0054

GLP-1(7-36), amide acetate Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0054B

GLP-1(7-36), amide TFA Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-P2534

C-Peptide 2, rat

Peptides Metabolic Disease

C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .

C-Peptide 2, rat	Peptides	Metabolic Disease
C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .

HY-P3863

Pancreastatin (swine)	Peptides	Inflammation/Immunology
Pancreastatin (swine) is a 49-residue peptide which strongly inhibits glucose-induced insulin release. Pancreastatin (swine) can be isolated and characterized from porcine pancreas .

HY-P1401

Protein Kinase C (19-36)	PKC	Metabolic Disease
Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC₅₀ of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P0055

GLP-1(7-37)

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
HY-P0055A

GLP-1(7-37) acetate

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .
HY-P5796

FS-2

Calcium Channel Neurological Disease

FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

GLP-1(7-37) 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

GLP-1(7-37) acetate 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

Magnesium Lithospermate B	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Simple Phenylpropanols Labiatae Source classification Samanea saman (Jacq.) Merr. Phenylpropanoids Plants Disease Research Fields	Others
Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroinﬂammation and attenuates neurodegeneration .

CMPF	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

Sulforaphane 30+ Cited Publications	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

(-)-Lyoniresinol 9'-O-glucoside	Structural Classification Albizia julibrissin Durazz. Leguminosae Source classification Plants Saccharides Monosaccharides	Reactive Oxygen Species
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

glucose-induced

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products